# First-line Chemotherapy for Recurrent Cervical Cancer

> **NCT04188847** · PHASE2 · COMPLETED · sponsor: **Lei Li** · enrollment: 37 (actual)

## Conditions studied

- Recurrent Cervical Carcinoma
- Persistent Advanced Cervical Carcinoma
- Chemotherapy
- Vascular Endothelial Growth Factor 2 Inhibitor
- Apatinib
- Targeted Therapy

## Interventions

- **DRUG:** Chemotherapy plus apatinib

## Key facts

- **NCT ID:** NCT04188847
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-06
- **Primary completion:** 2022-02-06
- **Final completion:** 2022-03-13
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188847, "First-line Chemotherapy for Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04188847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*